FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

NATCOPHARM

1,013
-25.9 (-2.49%)
Updated 03:29 28/07 IST

NATCOPHARM Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for NATCOPHARM
Disclaimer
0% Bullish
0% Bearish

NATCOPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
827
Consensus Potential
-25.62%
See NATCOPHARM Share Price Targets >>

NATCOPHARM Ratings

Long term NATCOPHARM rating by FrontPage users
5/5 (2 Ratings)
Find answers to all your questions on live NATCOPHARM message board: Is NATCOPHARM buy or sell? Should I buy NATCOPHARM shares? Why are NATCOPHARM shares falling? Should I invest in NATCOPHARM stock?

  1. Home
  2. NATCOPHARM Forum

NATCOPHARM Share Price Discussion

S
Reputation: 0 • Jul 27 3:34 AM

Type
Buy
Instrument
NATCOPHARM
Entry Price
₹1,066.6
Price@Trade
₹1,066.6
Target Price
₹1,300
Stop Price
₹1,050
Valid Till
Aug 27, 2021 3:20 AM
Margin
₹21,332 approx for 20 Qty
Status
Stoploss Hit
Exit Price
₹1,050
Net P&L
-₹332 (-1.56%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 27 5:00 AM

Update
Stoploss Hit
Exit Price
₹1,050

#NATCOPHARM :Natco Pharma says Delhi HC allows interim injunction application filed by FMC Corp alleging patent infringement by co for Chlorantraniliprole generic.
Natco Pharma says it will review all its options after full judgment becomes available (Negative)
Like
Reply
N
Reputation: 15,707 • Jul 1 2:46 AM
Buy Natco Pharma, target price Rs 1200: IIFL
Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 20592.32 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Reply

Type
Buy
Instrument
NATCOPHARM
Entry Price
₹1,134
Price@Trade
₹1,134.25
Target Price
₹1,300
Stop Price
₹1,050
Valid Till
Jul 30, 2021 3:20 AM
Margin
₹113,400 approx for 100 Qty
Status
Exited
Exit Price
₹1,153
Net P&L
+₹1,900 (+1.68%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 30 8:19 AM

Update
Trade Entered
Entry Price
₹1,134
PowerTrader  @powertrader
Jul 2 7:51 AM

Update
Exited
Exit Price
₹1,153
Net P&L
+₹1,900 (+1.68%)

Type
Sell
Instrument
NATCOPHARM
Entry Price
₹1,140
Price@Trade
₹1,137.6
Target Price
₹1,135
Stop Price
₹1,145
Valid Till
Jun 30, 2021 3:20 AM
Margin
₹912,000 approx for 800 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited before entry
Price @ Update
₹1,132.55

Type
Sell
Instrument
NATCOPHARM
Entry Price
₹1,140.5
Price@Trade
₹1,140.5
Target Price
₹1,135
Stop Price
₹1,145
Valid Till
Jun 30, 2021 3:20 AM
Margin
₹912,400 approx for 800 Qty
Status
Target Achieved
Exit Price
₹1,135
Net P&L
+₹4,400 (+0.48%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 30 8:06 AM

Update
Target Achieved
Exit Price
₹1,135
S
Reputation: 3,324 • Jun 30 7:35 AM
Shivansh in NATCOPHARM
#NATCOPHARM 10%
2
Reply
Like
Reply
Like
Reply
Like
Reply
N
Reputation: 15,707 • Jun 25 3:01 AM
Buy Natco Pharma, target price Rs 1150: Kotak Securities
Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 19969.64 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Reply
S
Reputation: 80 • Jun 21 3:51 AM
Like
Reply

Type
Buy
Instrument
NATCOPHARM
Entry Price
₹1,105
Price@Trade
₹1,105.2
Target Price
₹1,110
Stop Price
₹1,100
Valid Till
Jun 21, 2021 3:20 AM
Margin
₹221,000 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹1,100
Net P&L
-₹1,000 (-0.45%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 21 3:46 AM

Update
Trade Entered
Entry Price
₹1,105
TrackerBot @trackerbot
Jun 21 3:47 AM

Update
Stoploss Hit
Exit Price
₹1,100
Like
Reply

Type
Buy
Instrument
NATCOPHARM
Entry Price
₹1,079
Price@Trade
₹1,079.9
Target Price
₹1,090
Stop Price
₹1,069
Valid Till
Jun 25, 2021 3:20 AM
Margin
₹215,800 approx for 200 Qty
Status
Target Achieved
Exit Price
₹1,090
Net P&L
+₹2,200 (+1.02%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 18 8:01 AM

Update
Trade Entered
Entry Price
₹1,079
TrackerBot @trackerbot
Jun 18 8:30 AM

Update
Target Achieved
Exit Price
₹1,090
N
Reputation: 15,707 • Jun 17 12:46 PM
Natco Pharma Q4 results: Net profit dips 43% to Rs 53 crore
Total income during the fourth quarter stood at Rs 360 crore, down from Rs 477 crore in the fourth quarter of the financial year 2019-20, the drugmaker said in a regulatory filing.
The Economic Times
Like
Reply
N
Reputation: 15,707 • Jun 14 5:46 AM
Natco Pharma's marketing partner gets USFDA nod for anti-cancer drug
Natco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10 mg strength and shared 180 days of generic marketing exclusivity for the 60 mg strength of the product at the time of launch.
The Economic Times
Like
Reply

NATCOPHARM - chart - 3461472
#NATCOPHARM MEDIUM TERM BUY MODE TGT 1305/1592 SL 1045(WEEKLY CLBS)
Like
Reply

Type
Sell
Instrument
NATCOPHARM
Entry Price
₹1,083
Price@Trade
₹1,087
Target Price
₹1,000
Stop Price
₹1,085
Valid Till
May 25, 2021 3:20 AM
Margin
₹541,500 approx for 500 Qty
Status
Stoploss Hit
Exit Price
₹1,085
Net P&L
-₹1,000 (-0.18%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 25 3:10 AM

Update
Trade Entered
Entry Price
₹1,083
TrackerBot @trackerbot
May 25 3:10 AM

Update
Stoploss Hit
Exit Price
₹1,085
S
Reputation: 3,324 • May 25 5:49 AM
Shivansh in NATCOPHARM
#NATCOPHARM
2
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • NATCOPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization13,915.91
    Enterprise Value13,916.81
    Price to Earnings19.94
    Price to Book Value4.45
    Return on Capital Employed0.27
    Return on Equity0.22
    Face Value2
    Dividend Yield0.01
  • NATCOPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-Nov-20Geojit Financial ServicesReduce827
    9-Mar-20Geojit Financial ServicesSell534
    14-Feb-20Nirmal BangAccumulate685
    13-Aug-19Nirmal BangBuy654
    9-Aug-19AnandRathiBuy763
    NATCOPHARM Brokerage Price Target
  • NATCOPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 281035.051039.91004.051016.65
    Jul 2710591069.351022.31038.9
    Jul 261092.151092.1510551057.4
    Jul 231092.451101.451078.151094.45
    Jul 2210881096.61080.91092.45
  • NATCOPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,094.77
    30 Day Moving Average₹1,094.87
    50 Day Moving Average₹1,077.46
    100 Day Moving Average₹974.39
    200 Day Moving Average₹942.26
  • NATCOPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,0912,002.80.04
    Operating Profit9286920.34
    Profit Before Tax888634.10.4
    Net Income698494.80.41
  • NATCOPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds3,1261,699.70.84
    Total Liabilities612648.4-0.06
    Total Assets3,7372,348.10.59
  • NATCOPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity476329.80.44
    Cash from Investing Activity-1,131-290.62.89
    Cash from Financing Activity652-170.2-4.83
    Net Cash Flow-3-131-0.98
  • NATCOPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.190.21
    Return on Equity0.220.29
    Return on Capital Employed0.270.34
  • NATCOPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue1.92
    3 Year CAGR Growth in Operating Profit3.35
    3 Year CAGR Growth in EBIDTA3.26
    3 Year CAGR Growth in Net Income3.56
    3 Yr CAGR Growth - Diluted EPS-0.18
  • NATCOPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.75
    5 Year CAGR Growth in Operating Profit5.39
    5 Year CAGR Growth in EBIDTA5.15
    5 Year CAGR Growth in Net Income7.93
    3 Yr CAGR Growth - Diluted EPS0.52
  • NATCOPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 1 2:46 AM
    Buy Natco Pharma, target price Rs 1200: IIFL
    The Economic Times
    NewsBot
    Jun 25 3:01 AM
    Buy Natco Pharma, target price Rs 1150: Kotak Securities
    The Economic Times
    NewsBot
    Jun 17 12:46 PM
    Natco Pharma Q4 results: Net profit dips 43% to Rs 53 crore
    The Economic Times
    NewsBot
    Jun 14 5:46 AM
    Natco Pharma's marketing partner gets USFDA nod for anti-cancer drug
    The Economic Times
    NewsBot
    May 24 5:11 AM
    Natco Pharma shares hit upper circuit. Here's why
    The Economic Times
    NewsBot
    May 22 8:36 AM
    Natco Pharma gets American drug regulator's nod for generic cancer treatment drug
    The Economic Times
    NewsBot
    May 21 1:01 AM
    Natco initiates phase-3 clinical trials of Molnupiravir capsules for COVID-19 treatment
    The Economic Times
    NewsBot
    May 21 12:16 PM
    Yashoda Hospitals joins Natco for clinical trials of Molnupiravir for Covid patients
    The Economic Times
    NewsBot
    May 3 4:46 AM
    Natco gets emergency use nod for Baricitinib to treat Covid-19
    The Economic Times
    NewsBot
    Apr 30 2:01 AM
    Writ petition filed to issue CL for Covid drugs, regulate vaccine prices
    The Economic Times
  • NATCOPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020